Browse Category

Biotechnology 12 January 2026 - 17 January 2026

Thermo Fisher Scientific stock slips into long weekend as TMO traders eye Jan. 29 earnings

Thermo Fisher Scientific shares dipped 0.9% to close at $618.72 on Friday, then stayed close to that price in after-hours trading. During the day, the stock fluctuated between $618.20 and $629.50. Trading volume hit roughly 2.9 million shares, matching its typical daily activity.

17 January 2026

Biotechnology·Earnings Reports·NYSE:TMO·Stock Market

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie Inc shares dropped 1.1% to $214.35 Friday afternoon after releasing mixed results from a late-stage trial of its lymphoma drug epcoritamab. The Phase 3 study hit its primary endpoint, showing improved progression-free survival — meaning patients lived longer without their cancer worsening — but it missed a statistically significant gain in overall survival, the company said. AbbVie and partner Genmab said they plan to consult regulators on the next steps.

16 January 2026

Biotechnology·NYSE:ABBV·Pharmaceuticals·Stock Market

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio shares jumped about 35% on Friday after the cancer drugmaker reported faster enrollment and stronger interim results in a key bladder cancer study for its ANKTIVA therapy. The stock was up $1.39 at $5.34 by 12:51 p.m. EST after hitting $5.53, with about 133 million shares traded. The company said more than 85% of patients are enrolled in its QUILT-2.005 trial and it is targeting a U.S. filing by the end of 2026; an interim analysis showed 85% of patients on ANKTIVA plus BCG stayed in complete response at six months versus 57% on BCG alone and 84% versus 52% at nine months.

16 January 2026

Biotechnology·NASDAQ:IBRX·Pharmaceutical News·Stock Market

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares surged roughly 16.5% to $4.60 Friday morning, building on a strong rally after the biotech reported better-than-expected sales momentum for its main cancer drug. The company also detailed plans for a label-expansion effort. Trading volume exceeded 56 million shares, with the stock reaching an intraday peak of $5.20.

16 January 2026

Biotechnology·Health News·NASDAQ:IBRX·Stock Market

Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

Viridian Therapeutics shares climbed 6.4% to $34.03 in early afternoon trading on Wednesday, after hitting an intraday high of $34.25, a new 52-week peak.

14 January 2026

Biotechnology·NASDAQ:VRDN·Pharmaceuticals

Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals shares jumped over 10% Wednesday, fueled by the company’s newest conference update on its lead cancer drug. By midday, the stock had risen 10.4% to $38.03, after trading in a range from $34.05 to $38.35.

14 January 2026

Biotechnology·NASDAQ:TERN.O·Pharmaceuticals

Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data

Shares of Erasca Inc jumped roughly 10% Wednesday, pushing higher after a string of price-target upgrades fueled by early trial results. The clinical-stage cancer drugmaker's stock hit $8.29, up 10.5%.

14 January 2026

Biotechnology·NASDAQ:ERAS·Pharmaceutical Industry·Stock Market

KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

Kiniksa Pharmaceuticals International, plc saw its shares drop 6.1% to $38.61 on Tuesday, following the release of updated revenue forecasts for its key drug ARCALYST. The stock briefly dipped to an intraday low of $38.27. Yahoo Finance

13 January 2026

Biotechnology·Earnings Reports·NASDAQ:KNSA·Pharmaceuticals·Stock Market

GeneDx stock drops again: WGS slides on 2026 outlook as JPM talk nears

Shares of GeneDx Holdings Corp dropped roughly 8.7% to $108.90 Tuesday afternoon, continuing their slide after the genetic testing firm revealed its 2026 revenue forecast the previous day.

13 January 2026

Biotechnology·NASDAQ:WGS·Stock Market

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Shares of Structure Therapeutics climbed roughly 14% on Tuesday, adding to the stock’s recent swings. The move came as investors took a fresh look at the company’s newly announced patent licensing deal with Roche’s Genentech.

13 January 2026

Biotechnology·NASDAQ:GPCR·Pharmaceuticals·Stock Market·SWX:ROG

Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

Moderna shares were up $3.97, or 11.7%, at $37.81 by late morning in New York, lifting the vaccine maker to one of the stronger movers in biotech trading.

13 January 2026

Biotechnology·Earnings·NASDAQ:MRNA

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio, Inc. shares rose about 6% on Tuesday after the company released new lung cancer trial results tied to its immune-boosting drug ANKTIVA. The stock was up 6.4% at $2.76, after touching $2.85 earlier in the session.

13 January 2026

Biotechnology·NASDAQ:IBRX·Stock Market

Thermo Fisher (TMO) stock slips after-hours after Nvidia lab-automation tie-up, exec shake-up

Thermo Fisher Scientific Inc shares slipped roughly 0.5% in Monday’s after-hours session, following the life-sciences tools company’s announcement of a fresh partnership with Nvidia and a shake-up in its leadership team.

13 January 2026

Biotechnology·NASDAQ:HSIC·NASDAQ:NVDA·NYSE:TMO·Stock Market

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences shares dropped roughly 8.5% to $26.08 in afternoon trading, after fluctuating between $25.35 and $29.77 earlier today.

12 January 2026

Biotechnology·NASDAQ:CAI·Stock Market

GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

Shares of GeneDx Holdings Corp dropped roughly 14% Monday following the release of its 2026 outlook and preliminary results for 2025. The stock slipped $19.64 to trade at $115.75 in afternoon sessions.

12 January 2026

Biotechnology·Stock Market

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio Inc shares tumbled almost 18% on Monday following news of a licensing deal with Japan’s Eisai and initial sales data for its lung-cancer treatment. The stock slipped 17.7% to $6.62, after fluctuating between $8.34 and $6.32 on roughly 11.4 million shares traded.

12 January 2026

Biotechnology·Earnings Reports·NASDAQ:NUVB·Stock Market·TSX:4523

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Shares of Johnson & Johnson climbed roughly 2.3% to $209.03 on Monday, pushing the stock near the high end of its trading range after new oncology data came out over the weekend.

12 January 2026

Biotechnology·Earnings Reports·NYSE:JNJ·Pharmaceuticals

Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Shares of Twist Bioscience Corp jumped roughly 8% Monday following a preliminary first-quarter revenue report that beat expectations. The synthetic DNA company’s stock climbed 7.8% to $38.07 in afternoon trading, trading between $34.51 and $39.80 earlier in the session.

12 January 2026

Biotechnology·Earnings Reports·NASDAQ:TWST

BillionToOne stock jumps after fresh 2026 revenue outlook signals faster growth

BillionToOne shares climbed roughly 7% to $92.20 during Monday’s midday session, following the company’s release of its 2026 forecast.

12 January 2026

Biotechnology·NASDAQ:BTO·Stock Market

Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna shares dropped roughly 4% on Monday following the release of updated revenue and expense forecasts ahead of a healthcare investor event. The stock fell $1.38 to $32.92, after starting the day at $34.40 and fluctuating between $35.77 and $32.81.

12 January 2026

Biotechnology·Earnings Reports·NASDAQ:MRNA·Stock Market

Previous 1 … 6 7 8 9 10 … 21 Next

Biotechnology 12 January 2026 - 17 January 2026

Thermo Fisher Scientific stock slips into long weekend as TMO traders eye Jan. 29 earnings

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data

KNSA stock slides 6% after Kiniksa maps out $900–$920 million ARCALYST outlook — what’s next

GeneDx stock drops again: WGS slides on 2026 outlook as JPM talk nears

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

Thermo Fisher (TMO) stock slips after-hours after Nvidia lab-automation tie-up, exec shake-up

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

BillionToOne stock jumps after fresh 2026 revenue outlook signals faster growth

Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

TechStock² Updates

DoubleVerify (NYSE:DV) Rises 13% Following Nielsen Bid as Merger Gap Closes

Vistra (NYSE:VST) Shares Fall Despite 31% Rise in EBITDA, Maintains 2026 Outlook

Wendy’s (NASDAQ:WEN) to Slash Dividend, Releasing Approximately $53 Million as U.S. Sales Fall Behind Other Burger Chains

AXIA Energia Shares Hold Steady as R$7.7 Billion Capital Program Moves Forward

Chances of Fed Rate Hike Decline, Yet High-Yield Dividend Stocks Provide Little Protection

Top Stock Picks

Constellation Energy

AerCap

Walt Disney

AIG

Cheniere Energy

Live updates

Investment Disclaimer